Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Shanghai Menon Animal Nutrition Technology
301156
5
Nanjing Railway New Technology
301016
CN Stock MarketDetailed Quotes
000516 Xi'An International Medical Investment
- 5.60
- +0.06+1.08%
Market Closed Apr 3 15:00 CST
12.66BMarket Cap-35.44P/E (TTM)
5.68High5.48Low189.78KlotVolume5.48Open5.54Pre Close106.34MTurnover0.85%Turnover RatioLossP/E (Static)2.26BShares6.7752wk High3.47P/B12.46BFloat Cap4.0152wk Low6.09Limit Up2.22BShs Float21.66Historical High4.99Limit Down3.61%Amplitude0.00Historical Low--Dividend TTM5.60Avg Price91.15KlotAsk--Div YieldTTM100Lot Size93.67KlotBid
Xi'An International Medical Investment News
Xi'An International Medical Investment (000516.SZ): has cumulatively repurchased 0.4865% of shares.
Gelonghui, April 2 - Xi'An International Medical Investment (000516.SZ) announced that as of March 31, 2025, the company has cumulatively repurchased 10,997,100 shares through the centralized bidding trading system of the Shenzhen Stock Exchange, accounting for 0.4865% of the company's current total equity, with a highest Fill Price of 5.618 yuan/share and a lowest Fill Price of 4.61 yuan/share, totaling an amount of 57.4268 million yuan (excluding transaction costs).
Xi'An International Medical Investment (000516.SZ): The local deployment of the related Medical Asia Vets models has been completed.
Gelonghui reported on March 24 that Xi'An International Medical Investment (000516.SZ) stated on the investor interaction platform that the company has always paid attention to cutting-edge technology. Under the strict guarantee of data privacy and Cybersecurity, the relevant Medical Asia Vets models have been locally deployed, achieving connectivity with core Business systems such as HIS (Hospital Information System) and EMR (Electronic Medical Record System).
Xi'An International Medical Investment (000516.SZ): Currently, the cooperation with Alibaba is mainly focused on the technical level.
On March 24, the company Xi'An International Medical Investment (000516.SZ) stated on the investor interaction platform that its collaboration with Alibaba is currently focused on the technical level, specifically including the use of Alibaba's proprietary cloud solutions, as well as technical support and maintenance services for proprietary cloud version upgrades, resource expansion, and other aspects. The company has always maintained a focus on cutting-edge technologies, and under the strict guarantee of data privacy and Cybersecurity, it has completed the local deployment of related Medical intelligent models, achieving connectivity with core Business systems such as HIS (Hospital Information System) and EMR (Electronic Medical Record System).
Xi'An International Medical Investment (000516.SZ) has spent 57.427 million yuan to repurchase 10.9971 million shares.
Xi'An International Medical Investment (000516.SZ) issued an announcement that as of January 31, 2025, the company has accumulated through Shenzhen...
International Medicine: 2024 performance forecast
Xi'An International Medical Investment (000516.SZ): The proton therapy system is currently in the precision installation, debugging, and acceptance phase.
On January 3, Gelonghui reported that Xi'An International Medical Investment (000516.SZ) stated on the investor interactive platform that the Xi'An International Medical Investment is constructing a proton therapy center project. Currently, the proton therapy system has entered the precision installation, debugging, and acceptance phase, and it is expected to be completed and put into use by the end of 2025. Additionally, the company still has some land resources awaiting development. In the future, the company will further expand new business sectors such as life health management and integrated medical services based on the existing high-level Medical platform.
Xi'An International Medical Investment (000516.SZ): has cumulatively repurchased 0.49% of its shares.
On January 2, Glorious Group reported that Xi'An International Medical Investment (000516.SZ) announced that as of December 31, 2024, the company had cumulatively repurchased 10,997,100 shares through the Shenzhen Stock Exchange trading system via centralized bidding, accounting for 0.4865% of the company's current total share capital, with a maximum Fill Price of 5.618 yuan/share, a minimum Fill Price of 4.61 yuan/share, and a total transaction amount of 57.4268 million yuan (excluding transaction fees).
Xi'an international medical investment (000516.SZ): The maximum number of inpatient beds at Xi'an High-tech hospital has reached 1,680.
Gelonghui December 4th | Xi'an International Medical Investment (000516.SZ) stated in recent investor relations activities that recently, the maximum daily inpatient bed capacity of Xi'an Gaoxin Hospital has reached 1680 beds; the maximum daily inpatient bed capacity of the North and South campuses of Xi'an International Medical Investment Hospital has reached 3880 beds.
China Merchants Securities: Establishment of prepayment policy for medical insurance funds, releasing incremental signals at the bottom of the pharmaceutical sector.
It is reported that standardized prepayment process management, with the scale of regional prepayment in line with the approved standards for about one month, the prepayment system effectively alleviates the financial pressure of medical institutions, empowering the medical and pharmaceutical industry.
International Medicine: third quarter report 2024
xi'an international medical investment (000516.SZ): a net loss of 0.212 billion yuan in the first three quarters.
GeLongHui on October 24th, xi'an international medical investment (000516.SZ) announced its third-quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 3.606 billion yuan, a year-on-year increase of 7.85%; net income attributable to shareholders of the listed company was a loss of 0.212 billion yuan, a year-on-year increase of 4.59%; net income after deducting non-recurring gains and losses was a loss of 0.22 billion yuan, a year-on-year increase of 37.20%; basic earnings per share was -0.0954 yuan per share.
Obesity affects employment, eli lilly and co will try to use weight loss drugs to address the issue of unemployment in the united kingdom.
Peking time on the evening of the 15th, usa pharmaceutical giant eli lilly and co signed a major investment agreement with the united kingdom to explore the use of weight-loss drugs to curb unemployment. The weight-loss treatment company and the developer of the Zepbound drug announced on Monday that it will invest 0.279 billion british pounds (approximately 0.364 billion us dollars) to help address a major health challenge in the united kingdom—obesity, of course, being among them. The strategic cooperation between eli lilly and co and the UK Department of Health and Social Care (DHSC) and the Department of Science, Innovation and Technology (DSIT) is the first.
xi'an international medical investment (000516.SZ): accumulated repurchase of 0.4865% of the company's shares.
Gelonghui October 8 | xi'an international medical investment (000516.SZ) announced that as of September 30, 2024, the company has cumulatively repurchased 10,997,100 shares of the company through the Shenzhen Stock Exchange trading system through centralized bidding trading, accounting for 0.4865% of the company's current total share capital, with a highest fill price of 5.618 yuan/share, a lowest fill price of 4.61 yuan/share, and a total fill amount of 57,426,831.72 yuan (excluding transaction costs).
xi'an international medical investment (000516.SZ): the planned number of beds in its medical institutions is 10,137.
On September 30, Gelonhui reported that xi'an international medical investment (000516.SZ) stated on the investor interaction platform that the planned number of beds in the company's medical institutions is 10,137. Recently, Xi'an Gaoxin Hospital had an average daily inpatient bed usage of about 1500-1600 beds; Xi'an International Medical Center Hospital North and South regions had an average daily inpatient bed usage of about 3400-3500 beds.
International Medicine: 2024 Semi-Annual Report Summary
International Medicine: Semi-Annual Report 2024
Xi'an International Medical Investment (000516.SZ) released its performance for the first half of the year, with a net loss of 0.173 billion yuan.
xi'an international medical investment (000516.SZ) released the semi-annual report for 2024, with a revenue of 2.42 billion yuan, a year-on-year comparison...
Xi'an International Medical Investment (000516.SZ) has repurchased 0.4865% of its total shares.
Xi'an International Medical Investment (000516.SZ) announced that as of July 31, 2024, the company has repurchased 10,997,100 shares of company stock through the Shenzhen Stock Exchange trading system in a centralized bidding transaction, accounting for 0.4865% of the company's current total share capital. The highest fill price was 5.618 yuan/share and the lowest fill price was 4.61 yuan/share, with a total fill amount of 57,426,831.72 yuan (excluding transaction fees). The progress of the repurchase program complies with relevant laws and regulations and the established share repurchase program of the company.
Xi'An International Medical Investment: 2024 Interim Performance Forecast
Xi'an International Medical Investment (000516.SZ) has spent 57.43 million yuan to repurchase 10.9971 million shares.
Xi'an international medical investment (000516.SZ) announced that as of June 30, 2024, the company has cumulatively passed the Shenzhen...